Background. To date, little proteomic information has been available from the glomeruli of diabetic patients, possibly due to the clinical limitations of renal biopsy in diabetic patients and insufficient quantities of such specimens for proteome analysis. The purpose of the present study was to identify altered protein expression profiles in diabetic glomeruli using formalin-fixed paraffin-embedded (FFPE) kidney tissues from diabetic patients. Methods. Glomeruli were laser microdissected from FFPE autopsy kidney tissues from 10 patients with diabetic nephropathy and 10 non-diabetic control patients and underwent proteome analysis using QSTAR Elite liquid chromatography with tandem mass spectrometry and iTRAQ technology. Immunohistochemical analysis was performed on 93 autopsy samples from diabetic patients with and without nephropathy (n ¼ 45 and n ¼ 48, respectively). Results. Thirty-one renal and urological disease-related proteins displayed a differential abundance in glomerular samples from patients with diabetic nephropathy compared with non-diabetic control patients. Among them, we found that nephronectin, which functions in the assembly of extracellular matrix, showed clearly positive immunoreactivity in diabetic glomeruli. The numerical fraction of nephronectinpositive glomerular cross sections was increased significantly in diabetic patients with nephropathy compared to those without nephropathy (32.1 6 31.5 versus 4.14 6 5.65%, P < 0.0001). Furthermore, there was a significant positive correlation between this numerical fraction of nephronectinpositive glomerular cross sections and the glomerular sclerosis index (q ¼ 0.881, P < 0.0001, n ¼ 93).
Introduction
Diabetic nephropathy is the most frequent cause of endstage renal disease worldwide and currently accounts for 40% of patients that require renal replacement therapy [1] . It is a renal disease that arises as a consequence of diabetes and affects~30% of all such patients [2, 3] . The total number of people with diabetes is expected to increase from 171 million in 2000 to 366 million in 2030 [4] . Therefore, the number of people that develop diabetic nephropathy is also expected to increase. From this perspective, understanding the mechanisms and identification of novel biomarkers of diabetic nephropathy will be necessary to prevent the progression of diabetic nephropathy.
Recently, proteome analysis has increasingly been used in the discovery of disease-specific proteins and biomarkers of kidney diseases [5, 6] . Although proteome analysis of diabetic nephropathy has been performed using urine and serum specimens [7] [8] [9] [10] [11] , it is not clear whether the proteins that are differentially expressed in these studies correlate directly with diabetic glomerular alterations or are useful as novel biomarkers. Thus, in order to investigate protein expression profiles that reflect diabetic glomeruli, a full proteomic analysis of diabetic glomeruli is essential. However, proteome analysis of glomeruli isolated from kidney biopsy specimens of diabetic patients is difficult due to the fact that renal biopsy specimens are clinically limited in diabetic patients and the quantities of glomeruli obtained from renal biopsy specimens are usually not sufficient for proteome analysis. Compared with renal biopsy specimens, we expect that sufficient amounts of glomerular tissue specimen could be isolated from formalin-fixed paraffin-embedded (FFPE) autopsy kidney tissues for proteome analysis. Thus, research would be significantly advanced if FFPE kidney tissues of diabetic patients were made readily available for proteome analysis.
The purpose of the present study was to identify altered protein expression profiles in glomeruli from patients with diabetic nephropathy, using laser microdissected glomeruli from FFPE autopsy kidney tissues of diabetic patients with nephropathy and non-diabetic control patients, using QSTAR Elite liquid chromatography with tandem mass spectrometry (QSTAR Elite LC-MS/MS) and iTRAQ technology. Figure 1 indicates the workflow of this study. For the proteome analysis, 10 autopsy kidney specimens were obtained from diabetic patients with nephropathy, without hypertension or other renal disease, who did not undergo renal transplant, hemodialysis or peritoneal dialysis, during the period from December 2004 to December 2009 at Osaka City University Graduate School of Medicine. Ten control autopsy kidney specimens were obtained from age-matched non-diabetic patients without renal disease during the same period.
Materials and methods

Patients
For immunohistochemical analysis, in addition to the above specimens, 83 autopsy kidney specimens from diabetic patients were obtained during the period from January 1997 to December 2009 at Osaka City University Graduate School of Medicine. A total of 93 diabetic kidneys comprised of 45 and 48 cases with and without nephropathy, respectively, were obtained. All autopsy kidney tissues used in the present study were fixed in 10% buffered formalin and embedded in paraffin blocks. Before paraffin embedding, all autopsy kidney specimens were fixed in formaldehyde for 3-7 days.
Clinical data [i.e. fasting plasma glucose, hemoglobinA1c (HbA1c), urea nitrogen, creatinine and estimated glomerular filtration rate (eGFR)] were assessed 1 month before death to accurately reflect the long-term condition of the patient, as described previously [12] .
The Institutional Review Board at the Osaka City University Graduate School of Medicine approved the use of the autopsy specimens and clinical data in accordance with the Declaration of Helsinki and guidelines of the Osaka City University Graduate School of Medicine.
Collection of glomerular tissue specimen by laser microdissection
For each case, two 10-lm thick sections of FFPE kidney tissues that had been cut in 100-lm distance were placed on DIRECTORä slides (Expression Pathology, Gaithersburg, MD) for laser microdissection, deparaffinized and stained with hematoxylin. In each section, 20-25 fields of view (with three to eight glomerular cross sections per field) were randomly sampled at a magnification of 3100. The glomerular cross sections present in these fields were microdissected, using the Zeiss PALMÒ MB4 Microdissection System (Zeiss, Munich, Germany), according to the manufacturer's instruction, and collected into Adhesive Cap 500 clear tubes (Zeiss) containing 50 lL of liquid tissue buffer from the Liquid Tissueä MS Protein Prep kit. Images of a representative FFPE section of an autopsy kidney before and after laser microdissection and the microdissected glomerular cross sections on the microcentrifuge tube cap are shown in Figure 2 .
Based upon the results of our preliminary experiments, indicating that 1000 glomerular cross sections (5-lg protein) were necessary for proteome analysis, 100 glomerular cross sections were collected from two slides from each patient (50 glomerular cross sections per slide) by a random sampling method, and a total of 1000 glomerular cross sections from 10 diabetic patients with nephropathy were pooled. A total of 1000 glomerular cross sections from 10 non-diabetic patients without renal disease were pooled in a similar manner. The aim of the present study was to identify proteins that were commonly expressed in diabetic glomeruli and to compare them with those expressed in non-diabetic glomeruli. Since it was difficult to obtain sufficient amounts of glomeruli from individual diabetic patients with nephropathy or sufficient amounts of glomeruli from age-and sex-matched non-diabetic individual subjects and since multiple proteome analyses of each individual patient could therefore not be performed, we pooled the microdissected glomerular samples of 10 diabetic patients with nephropathy and of 10 non-diabetic patients, respectively.
Protein extraction, iTRAQ sample labeling and QSTAR Elite MS/MS analysis
Protein extraction was performed using the Liquid Tissueä MS Protein Prep kit, according to the manufacturer's protocol. Briefly, aliquots of tissue buffer-containing microdissected glomerular cross sections were heated at 95°C for 90 min and digested with 1.5 lL of 1 lg/mL trypsin overnight at 37°C. After brief ultrasonication, insoluble material was removed from the cell lysates by centrifugation at 13 000 g for 15 min at 10°C. Protein concentrations were determined using the BCA Protein Assay kit (Pierce, IL). Protein reduction, alkylation, digestion and subsequent peptide labeling were performed using the AB Sciex iTRAQ Reagent Multi-Plex Kit (AB Sciex, Foster City, CA), according to the manufacturer's instructions with minor modifications [13, 14] . Briefly, 6 lg of protein from each sample was incubated at 60°C for 60 min in 20 lL of dissolution buffer and 2 lL of reducing reagent [50 mM tris- 
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(2-carboxyethyl) phosphine]. Free cysteine sulfhydryl groups were blocked by incubation with 1 lL of cysteine blocking reagent (20 mM methyl methanethiosulfonate) at room temperature for 10 min. Nondiabetic samples and diabetic nephropathy samples were labeled with iTRAQ114 and iTRAQ115, respectively, mixed in one tube and fractionated by six concentrations of KCl solutions (10, 50, 70, 100, 200 and 350 mM) using the ICAT cation exchange cartridge (AB Sciex). After desalting and concentrating, peptides of each fraction were quantified using a DiNa-AI nano LC System (KYA Technologies, Tokyo, Japan) coupled to the QSTAR Elite MS/MS through a NanoSpray ion source (AB Sciex, Concord, Canada), as described previously [14] . Protein Pilot 2.0 software (AB Sciex) with the Paragonä Algorithm was used for the identification and relative quantification of proteins. Peptides were quantitated using the centroided reporter ion peak intensity. Intrasample channels were normalized, based on the median ratio for each channel across all proteins. Multiple isobaric tag samples were normalized by comparing the median protein ratios for the reference channel. Protein quantitative values were derived only from assigned peptides in both samples. Protein quantitative ratios statistics were calculated as the median of all peptide ratios [15, 16] . Statistically significant differences of protein expression were determined between the two groups using this software [14, 17] , and protein ratios with P-values <0.05 were considered reliable [16, 18] . The tandem mass spectrometry data were searched against the human protein database from SwissProt 57.4 (20 257 sequences). Furthermore, information regarding the function, cellular location and correlation to disease of the identified proteins was obtained from Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Mountain View, CA).
Nephronectin immunohistochemical analysis and evaluation of the numerical fraction of nephronectin-positive glomerular cross sections
Immunohistochemical staining was performed using the avidin-biotin immunoperoxidase method. Rabbit anti-human nephronectin antibody (Trans Genic Inc., Kumamoto, Japan) was used [1:100 dilution in phosphate-buffered saline (PBS)]. Briefly, after deparaffinization with xylene and gradual dehydration, antigen retrieval was undertaken with sodium citrate buffer at pH 6.0 in a microwave for 25 min and endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxide (H 2 O 2 ) for 5 min. Sections were then incubated with 1.5% normal goat serum in PBS for 15 min and the first antibody was applied at 4°C overnight. A biotinylated goat anti-rabbit IgG was applied as a secondary antibody for 30 min and the avidin-biotin peroxidase complex was applied for 30 min. Rabbit serum IgG was applied as a negative control. The peroxidase reaction was developed using 0.02% 3,3-diaminobenzidine tetrahydrochloride and 0.03% hydrogen peroxide in Tris-buffered saline. Hematoxylin was used for counterstaining. Glomeruli were defined as positive when positive staining of nephronectin was evident in >10% of the glomerular area. All glomeruli were counted in each specimen to calculate the numerical fraction of nephronectin-positive glomerular cross sections. Immunohistochemical analysis was carried out by two renal pathologists in a blinded manner.
Evaluation of glomerulosclerosis
FFPE kidney tissues were cut into 4-lm thick sections and stained with Periodic acid-Schiff. For evaluation of the glomerular sclerosis index, 20-25 fields of kidney sections (three to eight glomerular cross sections per field) were randomly selected at a magnification of 3100. The glomerular sclerosis index analysis was used to evaluate the degree of glomerulosclerosis [19, 20] . The severity of the lesions for each kidney was examined in 100 glomeruli using the random sampling method and graded from 0 to 4 points according to the proportion of morphological changes in each glomerulus (0, 0%; 11, 1-25%; 21, 26-50%; 31, 51-75%; 41, 76-100%). The number of glomeruli with lesions of grades 0, 11, 21, 31 and 41 was counted (n 0 , n 1 , n 2 , n 3 and n 4 , respectively). The glomerular sclerosis index was obtained according to the following formula: (0 3 n 0 1 1 3 n 1 1 2 3 n 2 1 3 3 n 3 1 4 3 n 4 )/100 [20] . Histological examinations were carried out by two renal pathologists in a blinded manner.
Statistical analysis
Statistical analyses were performed using Graph-Pad Prism version 5.0 for Windows (Graphpad Software, San Diego, CA). Values are expressed as the mean AE SD. Normality of variance was tested by the F-test. Differences in the mean values of eGFR, urinary protein, fasting plasma glucose, HbA1c, creatinine, urea nitrogen and the numerical fraction of nephronectin-positive glomerular cross sections between groups were analyzed by Student's t-test when variance was normal and by Welch's t-test when variance was not. The glomerular sclerosis index was analyzed by Mann-Whitney test. The number of male and female diabetes patients with and without nephropathy was analyzed by chi-square test. The relationship between the numerical fraction of nephronectin-positive glomerular cross sections and the glomerular sclerosis index was assessed by non-parametric Spearman's rank correlation test. P-values <0.05 were considered significant.
Results
Clinical characteristics
The clinical characteristics of the diabetic patients with nephropathy (n ¼ 10) and non-diabetic patients without renal disease (n ¼ 10), whose kidney specimens were used for proteome analysis, are summarized in Table 1 . The clinical characteristics of the diabetic patients with nephropathy were matched with non-diabetic patients, with respect to gender and age. Compared with non-diabetic patients, diabetic patients with nephropathy had significantly lower eGFR, significantly higher fasting plasma glucose and HbA1c levels (P < 0.05). The clinical characteristics of the 93 diabetic patients with and without nephropathy (including the 10 cases used in the above proteome analysis) in whom immunohistochemistry analyses were performed are summarized in Table 2 . Compared with diabetic patients without nephropathy, those with nephropathy had significantly lower eGFR, significantly higher urea nitrogen, creatinine and urinary protein (P < 0.05). On the other hand, age, gender, fasting plasma glucose and HbA1c were not significantly different between the diabetic patients with and without nephropathy.
Proteome analysis
A total of 170 proteins were identified by iTRAQ labeling and QSTAR Elite LC-MS/MS system with 95% confidence. A total of 100 proteins displayed a significant differential abundance in glomerular samples of diabetic patients with nephropathy as compared to non-diabetic patients. They consisted of 55 and 45 proteins that were overexpressed (Table 3) and downexpressed (Table 4) in glomerular cross sections from diabetic patients with nephropathy. Among them, 20 overexpressed and 11 downexpressed proteins were related to renal and urological disease, based on the results of IPA. In the present study, we focused on nephronectin because it was overexpressed in glomeruli from diabetic patients with nephropathy and because nephronectin has been reported to function in the assembly of extracellular matrix and could play a crucial role in the development of the kidney [21, 22] .
Analysis of glomerular nephronectin immunoreactivity
Consistent with a previous report [23] , nephronectin immunoreactivity was found to be negative in normal glomeruli but positive in tubular epithelial cells of non-diabetic patients ( Figure 3B ). In contrast, nephronectin immunoreactivity was clearly positive in mesangial expansion, diffuse glomerular sclerosis ( Figure 3D ) and nodular glomerulosclerosis ( Figure 3F ) in diabetic patients. Nephronectin
Nephronectin and diabetic glomerulosclerosis 1891 immunoreactivity was positive in some exudative lesions, but was much less well stained ( Figure 3H ) compared with the mesangial expansion lesions. No staining was observed in negative control specimens ( Figure 3I ). In contrast, nephronectin immunoreactivity was positive in tubular epithelial cells of mouse kidney sections, which were used as positive controls ( Figure 3J ). In the present study, positive glomerular immunohistochemical staining of nephronectin was restricted to the extracellular matrix of the glomeruli. We could not clearly find intracellular staining either in mesangial cells, podocytes or endothelial cells ( Figure 3D ). We further investigated nephronectin immunoreactivity in diabetic glomeruli in 93 diabetic patients, including those with and without nephropathy. As summarized in Table 5 , the numerical fraction of nephronectin-positive glomerular cross sections was significantly higher in the kidneys from diabetic patients with and without nephropathy compared with those from non-diabetic patients (32.1 AE 31.5 versus 0.54 AE 0.36%, P < 0.0001 and 4.14 AE 5.65 versus 0.54 AE 0.36%, P < 0.0001, respectively). The numerical fraction of nephronectin-positive glomerular cross sections in the kidneys from diabetic patients with nephropathy was significantly higher than in those without nephropathy (32.1 AE 31.5 versus 4.14 AE 5.65%, respectively, P < 0.0001).
Correlation analysis of the numerical fraction of nephronectin-positive glomerular cross sections and glomerulosclerosis
The results of the histological glomerular sclerosis index in 93 diabetic patients with and without nephropathy and 10 non-diabetic patients are shown in Table 5 . The glomerular sclerosis index in the kidneys from diabetic patients with nephropathy was significantly higher compared with that of the non-diabetic patients (1.51 AE 1.01 versus 0.25 AE 0.17, ) a The data are expressed as the mean 6 SD. P < 0.05. NA, not available; HbA1c, hemoglobin A1c. P < 0.0001, respectively). The glomerular sclerosis index in the kidneys from diabetic patients with nephropathy was significantly higher than in those without nephropathy (1.51 AE 1.01 versus 0.44 AE 0.35, P < 0.0001, respectively). There were no significant differences in the glomerular sclerosis index between diabetic patients without nephropathy and non-diabetic patients (0.44 AE 0.35 versus 0.25 AE 0.17, P ¼ 0.073, respectively). The relationship between the numerical fraction of nephronectin-positive glomerular cross sections and the glomerular sclerosis index in diabetic patients is shown in Figure 4 . There was a significant positive correlation between the numerical fraction of nephronectin-positive glomerular cross sections and the histological glomerular sclerosis index (q ¼ 0.881, P < 0.0001, n ¼ 93). There was a significant positive correlation between these parameters in diabetic patients with and without nephropathy (q ¼ 0.889, P < 0.0001 and 0.699, P < 0.0001, respectively, Table 5 ).
There was no significant correlation between these measures in non-diabetic patients (q ¼ 0.134, P ¼ 0.707).
Discussion
The present study implemented proteomic analysis of laser microdissected glomeruli from FFPE kidneys of autopsies of diabetic patients with nephropathy and nondiabetic patients using QSTAR Elite LC-MS/MS and iTRAQ technology identified 100 proteins that were differentially expressed. Among these proteins, 31 renal and urological disease-related proteins were detected. Nephronectin is one of the renal and urological disease-related proteins that were significantly overexpressed in samples of microdissected glomerular cross sections from diabetic patients with nephropathy. Immunohistochemical analysis demonstrated that glomerular nephronectin immunoreactivity was positive in diabetic patients in subjects with and without nephropathy, and was particularly positive in those with nephropathy, but negative in non-diabetic patients. Concerning the glomerular alterations in diabetic nephropathy, nodular glomerulosclerosis has been suggested to be a progressive form of diffuse mesangial expansion via a mesangiolytic step [24] that is specific to diabetic glomeruli. Mesangial expansion occurs due to the accumulation of extracellular matrix in the mesangium as a result of augmented deposition of extracellular matrix protein [25, 26] . Nephronectin has been reported to be associated with the assembly of extracellular matrix [27] [28] [29] and plays a crucial role during early metanephric kidney development [21, 22] . The findings of highly expressed nephronectin in glomeruli from diabetic patients with and without nephropathy but not in those from non-diabetic patients and the significant positive correlation between the numerical fraction of nephronectin-positive glomerular cross sections and the histological glomerular sclerosis index in diabetic patients both with and without nephropathy suggest that nephronectin is associated with the development of diabetic glomerulosclerosis and consequent nephropathy. Furthermore, the glomerular nephronectin immunoreactivity was also increased significantly in the glomeruli from diabetic patients without nephropathy compared with non-diabetic patients, despite the fact that there were no significant differences in the glomerular sclerosis index between these groups. This suggests that nephronectin may also be involved in the early stages of the development of glomerulosclerosis.
As mentioned above, nephronectin is associated with the assembly of extracellular matrix [27] [28] [29] and the accumulation of extracellular matrix in the mesangium is due to the augmented deposition of extracellular matrix protein, such as collagen Types I, IV, V, VI, laminin and fibronectin [25, 26] . In the current proteome analysis, collagen Types IV, VI, laminin and fibronectin were also overexpressed in glomerular cross sections from diabetic patients with nephropathy. These findings provide further evidence for the above notion that nephronectin is related to the diabetic glomerular alterations of diffuse mesangial expansion and nodular glomerulosclerosis. Although exudative lesions are often seen in diabetic kidneys, they are not specific to diabetic nephropathy and also appear to be due to increases in plasma lipoprotein [30] . In the present study, glomerular nephronectin immunoreactivity was positive in some exudative lesions, but was weakly positive, compared with strong immunoreactivity in diffuse mesangial expansion. This 
The data are expressed as the mean 6 SD. *P < 0.0001 versus non-diabetic patients. **P < 0.0001 versus with nephropathy. ***P < 0.0001 versus non-diabetic patients. ****P ¼ 0.073 versus non-diabetic patients. *****Correlation coefficients between the numerical fraction of nephronectin-positive glomerular cross sections and the glomerular sclerosis index.
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suggests that nephronectin is predominantly involved in the development of diffuse mesangial expansion and nodular glomerulosclerosis and that the levels of nephronectin may more appropriately reflect the status of diabetic nephropathy.
To the best of our knowledge, the present study is the first proteome analysis to use laser microdissected glomeruli from FFPE kidney tissues of diabetic nephropathy from human autopsy cases. In addition to nephronectin, apolipoprotein E is a well-known protein related to diabetic nephropathy [12, 31] , which we observed to also be significantly overexpressed in glomerular cross sections from diabetic patients with nephropathy in the present study. Consistent with a previous report [32] , collagen Type IV, an extracellular matrix protein that accumulates in sclerotic areas of diabetic glomeruli, was also overexpressed in the present study. The results of immunohistochemistry of apolipoprotein E and collagen Type IV were clearly positive in glomeruli from diabetic patients with nephropathy (Supplementary file). Furthermore, we also found that alphaactinin-4 and podocin, which are related to podocyte injury and proteinuria [33, 34] , exhibited reduced expression in diabetic patients with nephropathy. Therefore, it is reasonable to consider that the results of our proteome analysis reflected glomerular alterations of diabetic glomeruli to a great extent. We consider that nephronectin is thus demonstrated to be one of the proteins that are altered in glomeruli of patients with diabetic nephropathy. Our results also demonstrate the usefulness of proteome analysis of laser microdissected glomeruli from FFPE kidney tissues from autopsy patients in investigations of the molecular mechanisms of diabetic nephropathy. Although using microdissected glomerular samples from FFPE kidney tissues from autopsy material may reduce the detection of proteins compared with frozen tissue biopsies, the method in the present study enabled us to collect sufficient amounts of glomerular tissue. Since renal biopsy is clinically limited for diabetic patients and since sufficient quantities of renal biopsy specimens are not usually available for proteome analysis, we provide a new approach for investigations of renal disease, including diabetic nephropathy.
Recently, urinary-based proteome analyses of diabetic nephropathy have identified some proteins, such as collagen Type I, as candidate urinary biomarkers of diabetic nephropathy [7] [8] [9] . Proteome analysis of serum specimens from Type 2 diabetes patients has also shown that vitamin D-binding protein may be employed as a diagnostic and monitoring biomarker of microalbuminuria [10] and that extracellular glutathione peroxidase and apolipoprotein E may constitute potential biomarkers for the diagnosis of Type 2 diabetes with nephropathy [11] . However, expression of the above mentioned proteins in the kidneys from diabetic patients with nephropathy has not been investigated. Apart from apolipoprotein E, these proteins were not detected in the glomerular samples in the present study. The differences in the findings between the present study and the above urinary and serum studies could be attributed to differences in the samples examined and methods employed. The urine and serum levels of nephronectin were not examined in the present study due to the fact that urine and serum samples were not available from the autopsy cases investigated.
In conclusion, the present study demonstrated, for the first time, that nephronectin may be associated with the development of diabetic glomerulosclerosis and that proteome analysis of FFPE kidney tissues from diabetic patients with nephropathy is a useful tool for understanding diabetic nephropathy. Further studies with serum and urine are needed to evaluate the usefulness of nephronectin as a new biomarker that reflects glomerular alterations in diabetic nephropathy. Further studies are also needed to examine the role of nephronectin in other types of proliferative mesangial glomerulonephritis, such as IgA glomerulonephritis. Immunohistochemical staining of biopsy specimens obtained from living diabetic patients or from tumor nephrectomy tissues will be necessary for further proof of our findings.
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